A caspase-6 and anti-HER2 antibody chimeric tumor-targeted proapoptotic molecule decreased metastasis of human osteosarcoma

Cancer Investigation

Volumn 27, Issue 7, 2009, Pages 774-780

  Wang, Li Feng ^a   Zhou, Yong ^b   Xu, Yan Ming ^a   Qiu, Xiu Chun ^b   Zhou, Ben Gen ^b   Wang, Fang ^a   Long, Hua ^b   Chen, Xiang ^b   Yang, Tong Tao ^b   Ma, Bao An ^b   Fan, Qing Yu ^b   Yang, An Gang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Caspase 6; HER2 neu; Lung metastasis; Osteosarcoma

Indexed keywords

CASPASE 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IMMUNOCASP 6; LIPOFECTAMINE; PLASMID VECTOR; PSEUDOMONAS EXOTOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL KILLING; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIPOSOMAL DELIVERY; LUNG METASTASIS; METASTASIS INHIBITION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NUDE MOUSE; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; SURVIVAL TIME; TUMOR XENOGRAFT;

ADOLESCENT; AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; BONE NEOPLASMS; CASPASE 6; CELL LINE, TUMOR; GENE THERAPY; GENES, SYNTHETIC; HUMANS; IMMUNOTOXINS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; OSTEOSARCOMA; RANDOM ALLOCATION; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 68849111552     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802427935     Document Type: Article

References (29)

1. Hayden, J.B.; Hoang, B.H. Osteosarcoma: basic science and clinical implications. Orthop Clin North Am 2006, 37, 1-7.
2. Longhi, A.; Errani, C.; De Paolis, M.; Mercuri, M.; Bacci, G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006, 32, 423-436. (Pubitemid 44309249)
3. Chou, A.J.; Gorlick, R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 2006, 6, 1075-1085. (Pubitemid 44203385)
4. Shafique, Q.S.; Rajesh, C.M.; Rakesh, S.N. Cardiac metastases of osteosarcoma. J Coll Physicians Surg Pak 2004, 14, 430-432.
5. Fang, B.; Roth, J.A. Tumor-suppressing gene therapy. Cancer Biol Ther 2003, 2, S115-S121.
6. Mori, K.; Redini, F.; Gouin, F.; Cherrier, B.; Heymann, D. Osteosarcoma: current status of immunotherapy and future trends (review). Oncol Rep 2006, 15, 693-700.
7. Hynes, N.E.; Stern, D.F. The biology of erbB-2/neu/HER2 and its role in cancer. Biochim Biophys Acta 1994, 1198, 165-184.
8. Bargmann, C.I.; Hung, M.C.; Weinberg, R.A. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986, 319, 226-230. (Pubitemid 16128785)
9. Dougall, W.C.; Qian, X.; Peterson, N.C.; Miller, M.J.; Samanta, A.; Greene, M.I. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 1994, 9, 2109-2123. (Pubitemid 24228659)
10. Kim, Y.S.; Won, Y.S.; Park, K.S.; Song, B.J.; Kim, J.S.; Oh, S.J.; Jeon, H.M.; Jung, S.S.; Park, W.C. Prognostic significance of HER2 gene amplification according to stage of breast cancer. J Korean Med Sci 2008, 23, 414-420.
11. Somers, G.R.; Ho, M.; Zielenska, M.; Squire, J.A.; Thorner, P.S. HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissuemicroarray study. Pediatr Dev Pathol 2005, 8, 525-532.
12. Lee, W.I.; Bacchni, P.; Bertoni, F.; Maeng, Y.H.; Park, Y.K. Quantitative assessment of HER2/neu expression by real-time PCR and fluorescent in situ hybridization analysis in low-grade osteosarcoma. Oncol Rep 2004, 12, 125-128.
13. Thomas, D.G.; Giordano, T.J.; Sanders, D.; Biermann, J.S.; Baker, L. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin Cancer Res 2002, 8, 788-793. (Pubitemid 34742109)
14. Scotlandi, K.; Manara, M.C.; Hattinger, C.M.; Benini, S.; Perdichizzi, S.; Pasello, M.; Bacci, G.; Zanella, L.; Bertoni, F.; Picci, P.; Serra, M. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer 2005, 41, 1349-1361.
15. Gorlick, R.; Huvos, A.G.; Heller, G.; Aledo, A.; Beardsley, G.P.; Healey, J.H.; Meyers, P.A. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999, 17, 2781-2788.
16. Akatsuka, T.; Wada, T.; Kokai, Y.; Kawaguchi, S.; Isu, K.; Yamashiro, K.; Yamashita, T.; Sawada, N; Yamawaki, S.; Ishii, S. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 2002, 94, 1397-1404. (Pubitemid 34212632)
17. Riedl, S.J.; Shi, Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004, 5, 897-907. (Pubitemid 39486541)
18. Ruchaud, S.; Korfali, N.; Villa, P.; Kottke, T.J.; Dingwall, C.; Kaufmann, S.H.; Earnshaw, W.C. Caspase-6 gene disruption reveals a requirement for lamin A cleavage in apoptotic chromatin condensation. EMBO J 2002, 21, 1967-1977.
19. Srinivasula, S.M.; Ahmad, M.; MacFarlane, M.; Luo, Z.; Huang, Z.; Fernandes-Alnemri, T.; Alnemri, E.S. Generation of constitutively active recombinant caspase-3 and -6 by rearrangement of their subunits. J Biol Chem 1998, 73, 10107-10111.
20. Xu, Y.M.; Wang, L.F.; Jia, L.T.; Qiu, X.C.; Zhao, J.; Yu, C.J.; Zhang, R.; Zhu, F.; Wang, C.J.; Jin, B.Q.; Chen, S.Y.; Yang. A.G. A caspase-6 and anti-human epidermal growth factor receptor-2 (HER2) antibody chimeric molecule suppresses the growth of HER2-overexpressing tumors. J Immunol 2004, 173, 61-67.
21. Onn, A; Choe, D.H.; Herbst, R.S.; Correa, A.M.; Munden, R.F.; Truong, M.T.; Vaporciyan, A.A.; Isobe, T.; Gilcrease, M.Z.; Marom, E.M. Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome. Radiology 2005, 237, 342-347. (Pubitemid 41346185)
22. Komohara, Y.; Harada, M.; Arima, Y.; Suekane, S.; Noguchi, M.; Yamada, A.; Itoh, K.; Matsuoka, K. Identification of target antigens in specific immunotherapy for renal cell carcinoma. J Urol 2007, 177, 1157-1162. (Pubitemid 46216367)
23. Vermeij, J.; Teugels, E.; Bourgain, C.; Xiangming, J.; Veld, P. in 't; Ghislain, V.; Neyns, B.; De Greve, J. Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. BMC Cancer 2008, 8, 3.
24. Matsubara, J.; Yamada, Y.; Hirashima, Y.; Takahari, D.; Okita, N.T.; Kato, K.; Hamaguchi, T.; Shirao, K.; Shimada, Y.; Shimoda, T. Impact of Insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin Cancer Res 2008, 14, 3022-3029. (Pubitemid 351272605)
25. Fujimoto-Ouchi, K.; Sekiguchi, F.; Yasuno, H.; Moriya, Y.; Mori, K.; Tanaka, Y. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 2007, 59, 795-805. (Pubitemid 46440603)
26. Savellano, M.D.; Pogue, B.W.; Hoopes, P.J.; Vitetta, E.S.; Paulsen, K.D. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates. Cancer Res 2005, 65, 6371-6379.
27. Posey, J.A.; Khazaeli, M.B.; Bookman, M.A.; Nowrouzi, A.; Grizzle, W.E.; Thornton, J.; Carey, D.E.; Lorenz, J.M.; Sing, A.P.; Siegall, C.B.; LoBuglio, A.F.; Saleh, M.N. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin Cancer Res 2002, 8, 3092-3099.
28. Benbrook, D.M. An ELISA method for detection of human antibodies to an immunotoxin. J Pharmacol Toxicol Methods 2002, 47, 169-175. (Pubitemid 36287357)
29. Emens, L.A.; Davidson, N.E. Trastuzumab in breast cancer. Oncology (Huntingt) 2004, 18, 1117-1128.